These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16758308)

  • 1. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Salmerón J; De Rueda PM; Ruiz-Extremera A; Casado J; Huertas C; Bernal Mdel C; Rodríguez L; Palacios A
    Dig Dis Sci; 2006 May; 51(5):960-7. PubMed ID: 16758308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Salmerón J; Casado J; Rueda PM; Lafuente V; Diago M; Romero-Gómez M; Palacios A; León J; Gila A; Quiles R; Rodriguez L; Ruiz-Extremera A
    J Clin Virol; 2008 Apr; 41(4):264-9. PubMed ID: 18221912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
    Andriulli A; Nardi A; Di Marco V; Ippolito AM; Gavrila C; Aghemo A; Di Paolo D; Squadrito G; Grassi E; Calvaruso V; Valvano MR; Brancaccio G; Craxi A; Angelico M;
    Dig Liver Dis; 2014 Sep; 46(9):818-25. PubMed ID: 24953209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
    Abbate I; Lo Iacono O; Di Stefano R; Cappiello G; Girardi E; Longo R; Ferraro D; Antonucci G; Di Marco V; Solmone M; Craxì A; Ippolito G; Capobianchi MR
    J Hepatol; 2004 May; 40(5):831-6. PubMed ID: 15094232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
    Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
    J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
    Berg T; Sarrazin C; Herrmann E; Hinrichsen H; Gerlach T; Zachoval R; Wiedenmann B; Hopf U; Zeuzem S
    Hepatology; 2003 Mar; 37(3):600-9. PubMed ID: 12601358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.